Search the MBS

A test described in item 73320, if rendered by a receiving APP - 1 or more tests.

(Item is subject to rule 18 and 27)

Fee: $40.55 Benefit: 75% = $30.45 85% = $34.50

• Previous - Item 73320
• Next - Item 73323

Determination of HLAB5701 status by molecular techniques prior to the initiation of Abacavir therapy including item 71203 if performed.

Fee: $40.55 Benefit: 75% = $30.45 85% = $34.50

• Previous - Item 73321
• Next - Item 73324

A test described in item 73323 if rendered by a receiving APP

1 or more tests

(Item is subject to Rule 18)

Fee: $40.95 Benefit: 75% = $30.75 85% = $34.85

• Previous - Item 73323
• Next - Item 73325

Determination of JAK2 V617F variant allele frequency in the diagnostic work‑up by, or on behalf of, a specialist or consultant physician, for a patient with clinical and laboratory evidence of a myeloproliferative neoplasm

Fee: $90.00 Benefit: 75% = $67.50 85% = $76.50

• Previous - Item 73324
• Next - Item 73326

Characterisation of the gene rearrangement FIP1L1-PDGFRA in the diagnostic work-up and management of a patient with laboratory evidence of:

a)  mast cell disease; or

b)  idiopathic hypereosinophilic syndrome; or

c)  chronic eosinophilic leukaemia;.

1 or more tests

Fee: $230.95 Benefit: 75% = $173.25 85% = $196.35

• Previous - Item 73325
• Next - Item 73327

Detection of genetic polymorphisms in the Thiopurine S-methyltransferase gene for the prevention of dose-related toxicity during treatment with thiopurine drugs; including (if performed) any service described in item 65075.

1 or more tests

Fee: $51.95 Benefit: 75% = $39.00 85% = $44.20

• Previous - Item 73326
• Next - Item 73332

An in situ hybridization (ISH) test of tumour tissue from a patient with breast cancer requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to human epidermal growth factor receptor 2 (HER2) gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme (PBS) or the Herceptin Program are fulfilled.

Fee: $315.40 Benefit: 75% = $236.55 85% = $268.10

• Previous - Item 73327
• Next - Item 73333

Detection of germline mutations of the von Hippel‑Lindau (VHL) gene:

(a) in a patient who has a clinical diagnosis of VHL syndrome and:

(i) a family history of VHL syndrome and one of the following:

(A) haemangioblastoma (retinal or central nervous system);

(B) phaeochromocytoma;

(C) renal cell carcinoma; or

(ii) 2 or more haemangioblastomas; or

(iii) one haemangioblastoma and a tumour or a cyst of:

(A) the adrenal gland; or

(B) the kidney; or

(C) the pancreas; or

(D) the epididymis; or

(E) a broad ligament (other than epididymal and single renal cysts, which are common in the general population); or

(b) in a patient presenting with one or more of the following clinical features suggestive of VHL syndrome:

(i) haemangiblastomas of the brain, spinal cord, or retina;

(ii) phaeochromocytoma;

(iii) functional extra‑adrenal paraganglioma

Fee: $600.00 Benefit: 75% = $450.00 85% = $510.00

(See para PN.0.23 of explanatory notes to this Category)

• Previous - Item 73332
• Next - Item 73334

Detection of germline mutations of the von Hippel-Lindau (VHL) gene in biological relatives of a patient with a known mutation in the VHL gene

Fee: $340.00 Benefit: 75% = $255.00 85% = $289.00

(See para PN.0.23 of explanatory notes to this Category)

• Previous - Item 73333
• Next - Item 73335

Detection of somatic mutations of the von Hippel-Lindau (VHL) gene in a patient with:

    (a)    2 or more tumours comprising:

        (i)    2 or more haemangioblastomas, or

        (ii)    one haemangioblastoma and a tumour of:

            (A)    the adrenal gland; or

            (B)    the kidney; or

            (C)    the pancreas; or

            (D)    the epididymis; and

        (b)    no germline mutations of the VHL gene identified by genetic testing

Fee: $470.00 Benefit: 75% = $352.50 85% = $399.50

• Previous - Item 73334
• Next - Item 73336